At Axol Bioscience, we support your pursuit of more effective, safer therapies. Like you, we believe that having more human-relevant disease models will expand scientific knowledge and de-risk drug development. We use human iPSCs to achieve this and have been doing so since 2006. We use donated cells from patients and iPSC technology to build physiologically relevant in vitro models. We have a special focus on neurodegenerative diseases like Alzheimer's disease as well as cardiotoxicity to promote drug safety. When working with candidate compounds or novel therapies, our in vitro platforms give you better earlier-stage modeling and safety testing and later-stage efficacy evaluation and improved patient selection. With these data comes better insights, helping you de-risk projects, reduce costs, and save time during drug development.
Stay ahead of the competition with real-time market intelligence and actionable insights.
Disclaimer: All information contained in this database has been researched and compiled from many legitimate sources, believed to be accurate and reliable at the time of publishing. However, in view of the natural scope for human and/or mechanical error, either at source or during production, Dietary Business Intelligence (DBI) ( www.dbi360.com ) accepts no liability whatsoever for any loss or damage resulting from errors, inaccuracies or omissions affecting any part of the database. All information is provided without warranty, and DBI makes no representation of warranty of any kind as to the accuracy or completeness of any information hereto contained and strongly encourages that upon final material or product selection data points are validated with the supplier.
© Copyright 2026 Dietary Business Intelligence LLC. All Rights Reserved.
